India, Aug. 16 -- HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, reported financial results for the second quarter reflecting a wider net loss. In addition, the company provided an update citing funding needs.
HCW Biologics develops fusion immunotherapies to treat chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia.
The company's lead investigational pipeline includes HCW11-018b, a tetravalent T-cell engager; HCW11-040, a multifunctional fusion molecule; and HCW9302, which is in a clinical trial for alopecia areata.
Second Quarter Results
For the second quarter, net loss expanded to $5.2 million from $1.9 million in the prior year.
Revenue from licensing activities ro...